Financial Data and Key Metrics Changes - As of December 31, 2024, cash, cash equivalents, and investment-grade securities increased to approximately $9.3 million from $7.3 million as of December 31, 2023 [35] - Revenue for the year ended December 31, 2024, rose to approximately $3.495 million compared to $2.899 million the previous year, driven by license revenue and enzyme sales [35][36] - The net loss for the year ended December 31, 2024, was approximately $5.809 million or $0.20 per share, compared to a net loss of $6.795 million or $0.24 per share for the previous year [39] Business Line Data and Key Metrics Changes - The company emphasized strong revenue performance from milestone and license payments totaling $1.9 million, focusing on products that do not require human or animal clinical trials for commercialization [8] - Recombinant human serum albumin (RHSA) is on track for commercial launch in 2025, with significant progress in the commercialization of several cell culture media components [14][52] - The dairy enzyme portfolio achieved a productivity milestone of $425,000, with a commercial launch anticipated in late 2025 [18] Market Data and Key Metrics Changes - The human albumin market is approximately $5.6 billion and is expected to grow at double digits per year, driven by increased vaccine production [106] - The DNase I and DNA ligase market is around $900 million, also growing at nearly double digits annually [106] - The non-animal dairy proteins market is valued at $26 billion, indicating significant opportunities for products like alpha-lactalbumin and lactoferrin [107] Company Strategy and Development Direction - The company is focused on near-term product commercialization and technology licensing, with a dual-track strategy of commercializing non-pharmaceutical products while building a robust biopharmaceutical pipeline [9][10] - Partnerships with organizations like CEPI and the Gates Foundation are aimed at accelerating the development and adoption of the C1 platform for vaccines and treatments [11][26] - The company is committed to delivering sustainable value to shareholders and partners through a growing pipeline and strong collaborations [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's strategic focus on product commercialization and technology licensing, positioning it to capitalize on emerging opportunities [7] - The management highlighted the importance of ongoing partnerships and funding initiatives to support long-term innovation and market presence [25][29] - The company is seeing increased interest in its platforms and technology, indicating a positive outlook for future revenue generation [50] Other Important Information - The company received a $4.5 million grant from CEPI to support the development of recombinant protein vaccines using the C1 platform, with Dyadic expected to receive $2.4 million of this amount [25][40] - The company is also advancing its pipeline of innovations in both animal and human health, demonstrating the versatility of the C1 platform [29] Q&A Session Summary Question: Can you explain the Gates Foundation and CEPI grants and their significance? - Management confirmed ongoing interest from both organizations and highlighted the importance of these grants in advancing the C1 platform and driving innovation [45][46] Question: What is the status of albumin commercialization? - Management indicated that they are on track for commercialization in early 2025, emphasizing the need for product validation and quality assurance [52][56] Question: Can you clarify the components of research and development revenue? - Management noted that 80% of R&D expenses are covered by external funding, which supports the development of the C1 platform [61] Question: What is the market size opportunity for various products? - Management provided insights into the market sizes for human albumin, DNase I, and non-animal dairy proteins, highlighting significant growth potential in these areas [106][107] Question: What is the status of the work done in South Africa? - Management mentioned that the focus has shifted to animal health vaccines, with ongoing development and potential clinical studies expected by the end of the year [119][120]

Core Viewpoint - The article emphasizes the importance of nurturing and expanding emerging industries and future industries, focusing on strategic integration and innovation to drive economic growth. Group 1: Development of Emerging Industries - Deepen the integration and cluster development of strategic emerging industries [3] - Launch large-scale application demonstration actions for new technologies, products, and scenarios to promote the safe and healthy development of emerging industries such as commercial aerospace and low-altitude economy [3] - Establish a growth mechanism for future industry investments, nurturing sectors like biomanufacturing, quantum technology, embodied intelligence, and 6G [3] Group 2: Traditional Industry Transformation - Accelerate the high-quality development of key manufacturing industry chains, reinforcing industrial foundation reconstruction and major technological equipment breakthroughs [6] - Expand the scope and lower the thresholds for major technological transformation and large-scale equipment renewal projects in manufacturing [6] - Implement actions to enhance standards and optimize the upgrade of traditional industries, focusing on increasing product variety, improving quality, and creating brands [9] Group 3: Digital Economy Innovation - Continuously promote the "Artificial Intelligence +" initiative, integrating digital technology with manufacturing and market advantages to support the widespread application of large models [11] - Actively develop new generation intelligent connected vehicles, AI smartphones and computers, and intelligent robots [11]

As filed with the Commission on September 19, 2024 Registration No. 333-276987 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 6 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVIZYNE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2836 47-228900 (I.R.S. Employer Identification No.) 750 Royal Oaks D ...